
Mireia Castillo-Martin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1881454/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The "Immunoscore―in rectal cancer: could we search quality beyond quantity of life?. Oncotarget, 2022, 13, 18-31.	1.8	3
2	MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway. Cancer Letters, 2022, 525, 46-54.	7.2	19
3	PI3K-regulated Glycine N-methyltransferase is required for the development of prostate cancer. Oncogenesis, 2022, 11, 10.	4.9	6
4	PSMA expression in thyroid nodule. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 270-272.	0.2	0
5	Pancreatic intraductal papillary mucinous neoplasm associated colloid carcinoma. Radiology Case Reports, 2021, 16, 2989-2992.	0.6	3
6	Ct2n0 Distal Rectal Cancer - Do Not Believe In Fairy Tales!. Diseases of the Colon and Rectum, 2021, Publish Ahead of Print, e22.	1.3	0
7	The Role of Biobanks in the Fight against COVID-19 Pandemic: The Portuguese Response. Acta Medica Portuguesa, 2021, 35, .	0.4	0
8	Salvage Surgery With Organ Preservation for Patients With Local Regrowth After Watch and Wait: Is It Still Possible?. Diseases of the Colon and Rectum, 2020, 63, 1053-1062.	1.3	26
9	Impact of PSMA PET/CT in prostate cancer patient's clinical management: a pictorial essay of interesting cases with histologic confirmation. Clinical and Translational Imaging, 2020, 8, 207-226.	2.1	2
10	Zebrafish modeling of intestinal injury, bacterial exposures, and medications defines epithelial in vivo responses relevant to human inflammatory bowel disease. DMM Disease Models and Mechanisms, 2019, 12, .	2.4	30
11	Intragenic antagonistic roles of protein and circRNA in tumorigenesis. Cell Research, 2019, 29, 628-640.	12.0	121
12	Salvage surgery for local regrowths in Watch & Wait - Are we harming our patients by deferring the surgery?. European Journal of Surgical Oncology, 2019, 45, 1559-1566.	1.0	38
13	Transformed bone marrow cells generate neoplasms of distinct histogenesis. a murine model of cancer transplantation. Stem Cell Research, 2019, 41, 101637.	0.7	Ο
14	An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics, 2018, 50, 206-218.	21.4	229
15	PPARδ Elicits Ligand-Independent Repression of Trefoil Factor Family to Limit Prostate Cancer Growth. Cancer Research, 2018, 78, 399-409.	0.9	20
16	Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation. Journal of Cardiac Failure, 2018, 24, 78-86.	1.7	10
17	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nature Communications, 2018, 9, 3503.	12.8	224
18	Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. Oncogene, 2018, 37, 5858-5872.	5.9	20

#	Article	IF	CITATIONS
19	Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis. Journal of Clinical Investigation, 2018, 129, 215-222.	8.2	16
20	The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein. Journal of Cell Biology, 2017, 216, 641-656.	5.2	35
21	PTEN counteracts FBXL2 to promote IP3R3- and Ca2+-mediated apoptosis limiting tumour growth. Nature, 2017, 546, 554-558.	27.8	182
22	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature, 2017, 547, 109-113.	27.8	142
23	DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC) Journal of Clinical Oncology, 2017, 35, 300-300.	1.6	7
24	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. European Urology, 2016, 70, 771-775.	1.9	69
25	The metabolic co-regulator PGC1α suppresses prostate cancer metastasis. Nature Cell Biology, 2016, 18, 645-656.	10.3	176
26	Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. American Journal of Pathology, 2016, 186, 3131-3145.	3.8	28
27	H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases. Journal of Pediatric Urology, 2016, 12, 91.e1-91.e7.	1.1	10
28	Immunopathologic Assessment of PTEN Expression. Methods in Molecular Biology, 2016, 1388, 23-37.	0.9	8
29	Function of microRNA activity by ActMiR in bladder cancer Journal of Clinical Oncology, 2016, 34, 4531-4531.	1.6	0
30	Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC) Journal of Clinical Oncology, 2016, 34, e16002-e16002.	1.6	0
31	Concordance of Increased B1 Cell Subset and Lupus Phenotypes in Mice and Humans Is Dependent on BLK Expression Levels. Journal of Immunology, 2015, 194, 5692-5702.	0.8	41
32	MYC Drives <i>Pten/Trp53</i> -Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Cancer Discovery, 2015, 5, 636-651.	9.4	65
33	Suppression of <i>CHK1</i> by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. Cancer Discovery, 2015, 5, 550-563.	9.4	24
34	Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nature Communications, 2015, 6, 6087.	12.8	240
35	Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN. Methods, 2015, 77-78, 25-30.	3.8	16
36	A Genetic Platform to Model Sarcomagenesis from Primary Adult Mesenchymal Stem Cells. Cancer Discovery, 2015, 5, 396-409.	9.4	22

#	Article	IF	CITATIONS
37	Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR ^{â^'} /HER2 ⁺ breast cancers. Genes and Development, 2015, 29, 1631-1648.	5.9	94
38	Limited miR-17-92 overexpression drives hematologic malignancies. Leukemia Research, 2015, 39, 335-341.	0.8	19
39	<scp>PI</scp> 3K/ <scp>AKT</scp> pathway regulates Eâ€cadherin and Desmoglein 2 in aggressive prostate cancer. Cancer Medicine, 2015, 4, 1258-1271.	2.8	37
40	Loss of Sirt1 Promotes Prostatic Intraepithelial Neoplasia, Reduces Mitophagy, and Delays Park2 Translocation to Mitochondria. American Journal of Pathology, 2015, 185, 266-279.	3.8	51
41	ΔNp63 Expression is a Protective Factor of Progression in Clinical High Grade T1 Bladder Cancer. Journal of Urology, 2015, 193, 1144-1150.	0.4	21
42	The MicroRNA 424/503 Cluster Reduces CDC25A Expression during Cell Cycle Arrest Imposed by Transforming Growth Factor β in Mammary Epithelial Cells. Molecular and Cellular Biology, 2014, 34, 4216-4231.	2.3	39
43	FBXW7 Mutations in Melanoma and a New Therapeutic Paradigm. Journal of the National Cancer Institute, 2014, 106, dju107.	6.3	87
44	Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma. Journal of the American Academy of Dermatology, 2014, 70, 1036-1044.e3.	1.2	15
45	The <i>miR-424(322)/503</i> cluster orchestrates remodeling of the epithelium in the involuting mammary gland. Genes and Development, 2014, 28, 765-782.	5.9	66
46	Cross-Species Regulatory Network Analysis Identifies a Synergistic Interaction between FOXM1 and CENPF that Drives Prostate Cancer Malignancy. Cancer Cell, 2014, 25, 638-651.	16.8	293
47	RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of <i>Pten</i> -Mutant Metastasis. Cancer Discovery, 2014, 4, 318-333.	9.4	83
48	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nature Medicine, 2014, 20, 1130-1137.	30.7	349
49	Characterization of Desmoglein Expression in the Normal Prostatic Gland. Desmoglein 2 Is an Independent Prognostic Factor for Aggressive Prostate Cancer. PLoS ONE, 2014, 9, e98786.	2.5	43
50	ÂÂÂÂÂÂN-Me, a Long Range T-Cell Specific Oncogenic Enhancer in T-ALL. Blood, 2014, 124, 487-487.	1.4	0
51	Biomarkers for bladder cancer management: present and future. American Journal of Clinical and Experimental Urology, 2014, 2, 1-14.	0.4	36
52	A Common MicroRNA Signature Consisting of miR-133a, miR-139-3p, and miR-142-3p Clusters Bladder Carcinoma in Situ with Normal Umbrella Cells. American Journal of Pathology, 2013, 182, 1171-1179.	3.8	26
53	Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle, 2013, 12, 1722-1731.	2.6	25
54	A Molecular Signature Predictive of Indolent Prostate Cancer. Science Translational Medicine, 2013, 5, 202ra122.	12.4	114

MIREIA CASTILLO-MARTIN

#	Article	IF	CITATIONS
55	Preclinical Analysis of the Î ³ -Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics, 2012, 11, 1565-1575.	4.1	104
56	Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells. Cancer Cell, 2012, 22, 373-388.	16.8	368
57	A BAC-Based Transgenic Mouse Specifically Expresses an Inducible Cre in the Urothelium. PLoS ONE, 2012, 7, e35243.	2.5	12
58	PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation. Clinical and Translational Oncology, 2012, 14, 197-206.	2.4	16
59	Distinct Expression Profiles of p63 Variants during Urothelial Development and Bladder Cancer Progression. American Journal of Pathology, 2011, 178, 1350-1360.	3.8	114
60	Identification of PHLPP1 as a Tumor Suppressor Reveals the Role of Feedback Activation in PTEN-Mutant Prostate Cancer Progression. Cancer Cell, 2011, 20, 173-186.	16.8	158
61	Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis. Clinical and Translational Oncology, 2011, 13, 194-203.	2.4	15
62	Molecular pathways of urothelial development and bladder tumorigenesis. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 401-408.	1.6	228
63	Inactivation of <i>p53</i> and <i>Pten</i> promotes invasive bladder cancer. Genes and Development, 2009, 23, 675-680.	5.9	268
64	Characterization and comparison of the properties of sarcoma cell linesin vitroandin vivo. Human Cell, 2009, 22, 85-93.	2.7	16
65	Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. Journal of Clinical Investigation, 2008, 118, 3051-64.	8.2	319